
Vertex Pharmaceuticals guidance
$538.60−0.74%Close 13 Nov 2026
Vertex Pharmaceuticals gives no forecast in figures in its latest earnings release (2 Nov 2026). Many companies give their outlook on the call only, or none at all.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Guidance against results above 0 · within 1 · below 0
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Revenue | FY2026 | $13.10B to $13.20B | Raised once | — | To come |
|---|
| Tax rate · Adjusted | FY2026 | 19.5% to 20.5% | Given once | — | To come |
|---|
| Revenue | FY2025 | $11.90B to $12.00B | Raised twice | $12.00B | Within the range |
|---|
VRTX in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.